FBDD Fragments Base Drugs Discovery | Design
   
               
Search    
18-Jul-2014
  IOTA publishes review with Genentech scientists describing the use of mechanism-informed phenotypic screening (MIPS) in oncology drug discovery
   
2-Apr-2014
  IOTA Pharmaceuticals in 7.8M consortium tackling neglected parasitic diseases
   
21-Sep-2012
  IOTA InFarmatik Press Release
   
22-Feb-2011
  IOTA announces KINOMED, a new partnership to accelerate protein kinase drug discovery Cambridge, UK / Odense, Denmark / Lund, Sweden, February 22, 2011
   
17-Aug-2009
  New consortium to develop drugs for neglected tropical diseases
   
23-Apr-2008
  IOTA announces SPR initiative with Beactica AB
   
21-Dec-2007
  IOTA announces FBDD screening services
   
21-Dec-2007
  IOTA announces collaboration with Vitas M-laboratory and new FBDD library:IOTA-Vitas 4000
   
5-Aug-2007
  IOTA Pharmaceuticals established; research centers in the UK, the Netherlands, and India.
   
3-Aug-2007
  IOTA announces FBDD Initiative with the VU University, Amsterdam
   
25-Sep-2007
  IOTA announces first FBDD product: IOTA Diverse 1500
   
 
 
21st December 2007
 
New Fragment-based Drug Discovery Libraries announced in a commercial collaboration between IOTA Pharmaceuticals Ltd (Cambridge, UK) and Vitas-M Laboratory (Moscow, Russia)

IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Vitas-M Laboratory Ltd, based in Moscow, Russia, have joined forces to design and market the next generation of fragment-based drug discovery libraries for early-stage drug discovery.

The IOTA Pharmaceuticals - Vitas-M Laboratory collaboration couples IOTA Pharmaceuticals analysis and screening platforms to Vitas-M Laboratory's established chemical synthesis capabilities, to produce a new 4,000-component fragment-based drug discovery (FBDD) screening set. This fragment set is being distributed by both companies immediately.

Access to a diverse set of FBDD library compounds enables the rapid progression of new discovery programs from concept to optimised lead, as described in detail on the IOTA website.

Dr David Bailey, heading IOTA, commented "Fragment-based drug discovery (FBDD) is a fast, efficient and productive route to NCE discovery. Our combined technologies offer an extensive and reasonably-priced lead discovery tool kit for our pharma and biotech customers."

Vitas-M Laboratory is a specialist organic chemistry company which synthesises drug compounds for the pharmaceutical and biotechnology screening markets. For more information about Vitas-M Laboratory, please visit www.vitasmlab.com .
 
 
Copyright 2007 IOTA Pharmaceuticals  |   Site by Dots & Coms